Anti-human interleukin-36 receptor monoclonal antibody and its use
A novel anti-human IL-36R monoclonal antibody, QX009N, addresses the inadequacies of current treatments by blocking IL-36R-mediated inflammatory pathways, offering superior efficacy in reducing inflammatory responses and treating diseases like generalized pustular psoriasis and inflammatory bowel disease.
Patent Information
- Application Number
- JP2025522529
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-10-20
- Filing Date
- 2022-11-28
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-11-28
AI Technical Summary
Current treatments for IL-36R-mediated inflammatory diseases, such as generalized pustular psoriasis and inflammatory bowel disease, are inadequate in effectively blocking IL-36 inflammatory pathways and reducing disease-causing cellular inflammatory factors.
Development of a novel anti-human IL-36R monoclonal antibody, QX009N (HZD25-54), which competitively blocks IL-36R receptor agonists and downregulates pro-inflammatory signaling pathways, inhibiting inflammatory responses in epithelial cells and immune cells.
QX009N exhibits superior cellular-level neutralizing activity compared to spesolimab, effectively blocking IL-36 inflammatory pathways and reducing the release of inflammatory factors, demonstrating potential for treating IL-36R-mediated diseases.
Smart Images

Figure 0007948657000002 
Figure 0007948657000003 
Figure 0007948657000004
Abstract
Description
[Technical Field]
[0001] This application relates to the field of antibody drugs. Specifically, this application relates to a monoclonal antibody against the human interleukin-36 receptor (IL-36R) and its use. [Background technology]
[0002] Interleukin-36 (IL-36) belongs to the IL-1 family (IL1F) and consists of the IL-36 receptor agonists IL-36α (IL1F6), IL-36β (IL1F8), IL-36γ (IL1F9), and the IL-36 receptor antagonist IL-36Ra (IL1F5). Its structural pattern is similar to the classical IL-1 family: it lacks a signaling peptide and cannot be secreted via the classical Golgi endoplasmic reticulum pathway; it usually first forms an inactive precursor and is then activated by protease hydrolysis. IL-36 can be produced by various cells, including monocytes, macrophages, T / B lymphocytes, keratinocytes, and epithelial cells. The IL-36 receptor consists of a specific receptor, IL-36R (also known as IL-1RL2 or interleukin-1 receptor-like 2), and an IL-1 receptor accessory protein, IL-1RAcP (IL-1 receptor accessory protein). Both consist of an extracellular domain, a transmembrane domain, and an intracellular Toll / IL-1 receptor (TIR) domain, each comprising three domains. Matured agonist IL-36 ligands (α, β, γ) through protein hydrolysis bind to IL-36R to form a two-component complex, which then recruits IL-1RAcP to assemble into a functional three-component complex. Intracellular TIRs of IL-36R and IL-1RAcP interact to aggregate the signaling adapter proteins myeloid differentiation factor 88 (MyD88) and interleukin-1 receptor associated kinase (IL-1 receptor associated kinase, IRAK), activating the downstream NF-κB (nuclear factor kappa-B) and MAPK (mitogen-activated protein kinase) signaling pathways. When IL-36 is normally expressed, it can defend the host through an inflammatory response.When IL-36 expression is dysregulated, it stimulates receptor-expressing cells (epithelial cells, fibroblasts, keratinocytes, monocytes, macrophages, dendritic cells, and T cells) to produce inflammatory cytokines, chemokines, and adhesion molecules, further mediating pathological inflammatory responses and contributing to the pathological processes of chronic inflammatory diseases and autoimmune diseases such as generalized pustular psoriasis, palmoplantar pustulosis, atopic dermatitis, inflammatory bowel disease, and chronic obstructive pulmonary disease. [1]Town JE, Garka KE, Renshaw BR, et al.Interleukin (IL)-1F6,IL-1F8,and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs [J].Journal of Biological Chemistry,2004,279(14):13677-13688. [2] Gabay C, Towne J E. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions [J]. Journal of Leukocyte Biology, 2015, 97(4):645. [3]Henry CM, Sullivan GP, Clancy DM, et al.Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines[J].Cell Reports,2016,14(4):708-722. [4]Town JE, Renshaw BR, Douangpanya J, et al.Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36α,IL-36β,and IL-36γ) or Antagonist (IL-36Ra) Activity [J].Journal of Biological Chemistry,2011,286(49):42594-602. [5]Buhl,AL,Wenzel,J.Interleukin-36 in Infectious and Inflammatory Skin Diseases[J].Frontiers in Immunology,2019.01162 [Disclosure of the Invention]
[0003] This application aims to provide a novel anti-human IL-36R monoclonal antibody, a pharmaceutical composition containing the monoclonal antibody, and pharmaceutical applications for the monoclonal antibody.
[0004] The aspects of this application are as follows:
[0005] 1. An anti-human IL-36R monoclonal antibody comprising three heavy chain complementarity-determining regions (CDR-H1, CDR-H2, and CDR-H3) and three light chain complementarity-determining regions (CDR-L1, CDR-L2, and CDR-L3), The amino acid sequence of CDR-H1 (in this specification, CDR-H1 represents heavy chain CDR1) is shown in SEQ ID NO: 1 (NYAMG); The amino acid sequence of the aforementioned CDR-H2 (in this specification, CDR-H2 represents heavy chain CDR2) is shown in Sequence ID No. 2 (YISGGGSAYYASWAKG); The amino acid sequence of the aforementioned CDR-H3 (in this specification, CDR-H3 represents heavy chain CDR3) is shown in SEQ ID NO: 3 (WAIKSYFFGMDL); The amino acid sequence of CDR-L1 (in this specification, CDR-L1 represents light chain CDR1) is shown in Sequence ID No. 4 (QASEYISSYLA); The amino acid sequence of the aforementioned CDR-L2 (in this specification, CDR-L2 represents the light chain CDR2) is shown in Sequence ID No. 5 (QASTLAS); The monoclonal antibody wherein the amino acid sequence of CDR-L3 (in this specification, CDR-L3 represents light chain CDR3) is shown in SEQ ID NO: 6 (QTNNAIHTYGGA).
[0006] 2. Includes heavy chain variable region and light chain variable region, The amino acid sequence of the heavy chain variable region is shown in Sequence ID No. 7, and its amino acid sequence is EVQLVESGGGLVQPGGSLRLSCAASGIDLSNYAMGWVRQAPGKGLEWVGYISGGGSAYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWAIKSYFFGMDLWGQGTLVTVSS, The monoclonal antibody described in item 1, wherein the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 8, and its amino acid sequence is DIQMTQSPSSVSASVGDRVTITCQASEYISSYLAWYQQKPGKAPKLLIYQASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQTNNAIHTYGGAFGGGTKVEIK.
[0007] 3. An isolated nucleic acid encoding a monoclonal antibody as described in any one of the preceding items.
[0008] 4. Host cells containing the nucleic acids described in item 3.
[0009] The nucleic acid can be present on the vector. The vector may be of any type, for example, a recombinant vector such as an expression vector. Any of several host cells can be used. In one embodiment, the host cell is a prokaryotic cell, for example, Escherichia coli (E. coli). In another embodiment, the host cell is a eukaryotic cell, for example, a mammalian cell such as Chinese hamster ovary (CHO) cells.
[0010] 5. A method for producing a monoclonal antibody, comprising culturing the host cells described in item 4 to produce the monoclonal antibody described in any one of the preceding items.
[0011] The method comprises producing the monoclonal antibody by expressing a recombinant vector encoding the anti-human IL-36R monoclonal antibody in a suitable host cell. In certain embodiments, the method comprises expressing the nucleic acid by culturing a host cell containing the nucleic acid encoding the anti-human IL-36R monoclonal antibody. The method may further comprise recovering the anti-human IL-36R monoclonal antibody from a host cell culture or host cell culture medium.
[0012] 6. A pharmaceutical composition comprising a monoclonal antibody as described in any one of the preceding paragraphs and a pharmaceutically acceptable carrier.
[0013] The pharmaceutical composition may further contain other therapeutic agents (e.g., different anti-human IL-36R antibodies).
[0014] 7. A pharmaceutical composition according to item 6, used for the treatment of diseases related to IL-36R-mediated signaling.
[0015] 8. The diseases associated with IL-36R-mediated signaling are selected from dermatitis, psoriasis, inflammatory bowel disease, arthritis, systemic lupus erythematosus, inflammatory lung disease, and chronic kidney disease. Preferably, the disease associated with the IL-36R-mediated signaling is selected from generalized pustular psoriasis, palmoplantar pustulosis, atopic dermatitis, inflammatory bowel disease, chronic obstructive pulmonary disease, psoriasis vulgaris, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, scleroderma, asthma, or ankylosing spondylitis, according to claim 7.
[0016] 9. Use of any one of the monoclonal antibodies described in the preceding paragraphs in the preparation of drugs for treating diseases related to IL-36R signaling.
[0017] 10. The disease associated with IL-36R-mediated signal transduction is selected from dermatitis, psoriasis, inflammatory bowel disease, arthritis, systemic lupus erythematosus, inflammatory lung disease and chronic kidney disease, The use according to item 9, wherein preferably, the disease associated with IL-36R-mediated signal transduction is selected from generalized pustular psoriasis, palmoplantar pustulosis, atopic dermatitis, inflammatory bowel disease, chronic obstructive pulmonary disease, psoriasis vulgaris, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, scleroderma, asthma or ankylosing spondylitis.
[0018] 11. A method for treating a disease associated with IL-36R-mediated signal transduction, comprising, The method, comprising administering the monoclonal antibody according to any one of the preceding items or the pharmaceutical composition according to any one of the preceding items to a subject in need thereof.
[0019] 12. The disease associated with IL-36R-mediated signal transduction is selected from dermatitis, psoriasis, inflammatory bowel disease, arthritis, systemic lupus erythematosus, inflammatory lung disease and chronic kidney disease, The method according to item 11, wherein preferably, the disease associated with IL-36R-mediated signal transduction is selected from generalized pustular psoriasis, palmoplantar pustulosis, atopic dermatitis, inflammatory bowel disease, chronic obstructive pulmonary disease, psoriasis vulgaris, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, scleroderma, asthma or ankylosing spondylitis.
[0020] This application provides a novel anti-human IL-36R monoclonal antibody that has equivalent binding affinity to IL-36R as the conventional anti-human IL-36R monoclonal antibody spesolimab, but exhibits superior cellular-level neutralizing activity compared to spesolimab. Spesolimab is an IL-36R-targeting monoclonal antibody drug developed by Boehringer Ingelheim. The Phase 3 clinical trial NAVIGATOR for spesolimab, aimed at treating generalized pustular psoriasis in adults, was successful, and it is currently approved for sale by the U.S. Food and Drug Administration and has received priority review status from the China National Medical Products Administration. The monoclonal antibody of this application (e.g., QX009N(HZD25-54)) may be an IgG1 (immunoglobulin G1) type humanized monoclonal antibody that targets IL-36R (interleukin-36 receptor), has high affinity for IL-36R, specifically binds to IL-36R, and can block IL-36 inflammatory pathway signaling. HZD25-54 binds to IL-36R, competitively blocking the binding of receptor agonists (IL-36α, β, γ) to IL-36R, downregulating downstream pro-inflammatory and pro-fibrotic signaling pathways, inhibiting inflammatory responses mediated by epithelial cells / fibroblasts / immune cells, thereby reducing the release of disease-causing cellular inflammatory factors in inflammatory / skin diseases and achieving the objective of disease control.
[0021] The monoclonal antibody of this application exhibits superior neutralizing activity at the cellular level compared to spesorimab (expressed according to the sequence disclosed in the patent), and is expected to show favorable clinical efficacy in the prevention and treatment of related diseases. [Brief explanation of the drawing]
[0022] The attached drawings are provided for the purpose of better understanding this application and do not constitute any unwarranted limitation thereto. [Figure 1]Figure 1 shows the results of nucleic acid electrophoresis to construct the HZD25-54 transient expression plasmid. In this figure, M: Marker; Band 1: PCR product 25VH-Hu12; Band 2: pQX1, HindIII / BamHI; Band 3: PCR product 25VK-Hu17; Band 4: pQX2.3, HindIII / BsiHI. [Figure 2] Figure 2 is a flowchart of transient symptoms. [Figure 3] Figure 3 shows the electrophoretic detection diagram of QX009N(HZD25-54). [Figure 4] Figure 4 shows the activity of QX009N (HZD25-54) and spesolimab analogs in neutralizing human IL-36 (α, β, γ)-induced STAT3 phosphorylation in HT29 reporter gene cells. [Figure 5] Figure 5 shows the activity of QX009N (HZD25-54) and spesolimab analogs in neutralizing the release of CXCL-1 and IL-8 from HT29 cells induced by human IL-36 (α, β, γ). [Figure 6] Figure 6 shows the activity of QX009N (HZD25-54) and spesolimab analogs in neutralizing the release of CXCL-1 and IL-8 from A431 cells induced by human IL-36 (α, β, γ). [Figure 7] Figure 7 shows the activity of QX009N(HZD25-54) and spesolimab analogs in neutralizing IL-8 release from PBMC cells induced by human IL-36β. [Overview of the project]
[0023] The following describes exemplary embodiments of this application, which include various details of the embodiments of this application for the sake of ease of understanding, and should be considered merely as examples. Those skilled in the art will therefore recognize that various changes and modifications of the embodiments described herein can be made without departing from the scope and spirit of this application. Furthermore, for clarity and brevity, well-known functional and structural descriptions have been omitted in the following description.
[0024] The scientific and technical terms used herein have the same meanings as those generally understood by those skilled in the art; however, in case of any inconsistency, the definitions provided herein shall prevail.
[0025] Generally speaking, the terms used in this specification have the following meanings:
[0026] In this specification, “isolated” antibody means an antibody isolated from its natural environment. In some embodiments, the antibody is purified to a purity of 95% or greater than 99%, and this purity is determined, for example, by electrophoresis (e.g., SDS-PAGE isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse-phase HPLC). For a review of methods for evaluating antibody purity, see, for example, Flatman et al., J. Chromatogr. B848:79-87 (2007).
[0027] In this specification, “monoclonal antibody” means an antibody obtained from a substantially homologous group of antibodies, i.e., each antibody constituting the group is identical and / or binds to the same epitope. Except for possible variant antibodies (e.g., those containing naturally occurring mutations or those generated during the manufacturing process of monoclonal antibody products), such variants are generally present in trace amounts. Unlike typical polyclonal antibody products, which contain different antibodies against different determinants (epitopes), each monoclonal antibody in a monoclonal antibody product is against a single determinant on an antigen. Therefore, the modifier “monoclonal” indicates a characteristic obtained from a substantially homologous group of antibodies and should not be interpreted as an antibody that needs to be prepared by any particular method. For example, the monoclonal antibodies of this application can be prepared by several techniques, which include, but are not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of a human immunoglobulin locus. This text describes such methods and other exemplary methods for preparing monoclonal antibodies.
[0028] In this specification, “affinity” refers to the sum of the non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, “binding affinity” as used herein refers to the intrinsic binding affinity that reflects the 1:1 interaction between binding partner members (e.g., an antibody and an antigen). The affinity of molecule X to partner Y can generally be expressed by the equilibrium dissociation constant (KD). Affinity can be measured by commonly used methods known in this art.
[0029] In this specification, the human interleukin-36 receptor (hIL-36R; sometimes abbreviated as IL-36R) refers to a human-derived membrane receptor, the amino acid sequence of its extracellular region is shown in SEQ ID NO: 9, and the underlined portion represents the signal peptide. Sequence ID 9: MWSLLLCGLSIALPLSVTADGCKDIFMKNEILSASQPFAFNCTFPPITSGEVSVTWYKNSSKIPVSKIIQSRIHQDETWILFLPMEWGDSGVYQCVIKGRDSCHRIHVNLTVFEKHWCDTSIGGLPNLSDEYKQILHLGKDDSLTCHLHFPKSCVLGPIKWYKDCNEIKGERFTVLE TRLLVSNVSAEDRGNYACQAILTHSGKQYEVLNGITVSITERAGYGGSVPKIIYPKNHSIEVQLGTTLIVDCNVTDTKDNTNLRCWRVNNTLVDDYYDESKRIREGVETHVSFREHNLYTVNITFLEVKMEDYGLPFMCHAGVSTAYIILQLPAPDFR
[0030] In this specification, "anti-human IL-36R monoclonal antibody" means a monoclonal antibody that can bind to human IL-36R with sufficient affinity so that it can be used as a diagnostic and / or therapeutic agent targeting human IL-36R.
[0031] The anti-human IL-36R monoclonal antibody of this application does not bind to unrelated target proteins. Here, "unrelated proteins" refers to proteins other than the target human IL-36R, and "does not bind" means that, if the binding ability of the anti-human IL-36R monoclonal antibody of this application to its target human IL-36R is considered to be 100%, the binding ability of the anti-human IL-36R monoclonal antibody of this application to those unrelated proteins is less than 10%, for example, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.
[0032] The anti-human IL-36R monoclonal antibody of this application may not bind to IL-36R in other animal species. Here, "other animal species" refers to animal species other than humans, such as marmosets, cynomolgus monkeys, pigs, dogs, rabbits, rats, mice, guinea pigs, etc. Here, "does not bind" means that, if the binding ability of the anti-human IL-36R monoclonal antibody of this application to its target human IL-36R is considered to be 100%, the binding ability of the anti-human IL-36R monoclonal antibody of this application to IL-36R in other animal species is less than 10%, for example, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0%.
[0033] The human IL-36R monoclonal antibody of this application has equilibrium dissociation constants (K) of, for example, 1 μM or less, 100 nM or less, 50 nM or less, and 40 nM or less. D ) can have.
[0034] The experimental results demonstrate that the anti-human IL-36R monoclonal antibody of this application can specifically bind to human IL-36R.
[0035] The anti-human IL-36R monoclonal antibody of this application is equivalent to or superior to commercially available monoclonal antibody products of the same type in many biological activities. Such biological activities include, for example, the activity of neutralizing STAT3 phosphorylation in cells induced by human IL-36(α,β,γ), the activity of neutralizing the release of CXCL-1 and IL-8 from cells induced by human IL-36(α,β,γ), and the activity of neutralizing the release of IL-8 from human PBMC cells induced by human IL-36β.
[0036] In one particular embodiment, the amino acid sequence of the heavy chain of the anti-human IL-36R monoclonal antibody of this application may be shown in SEQ ID NO: 10, and the amino acid sequence of the light chain may be shown in SEQ ID NO: 11. Sequence ID 10 EVQLVESGGGLVQPGGSLRLSCAASGIDLSNYAMGWVRQAPGKGLEWVGYISGGGSAYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWAIKSYFFGMDLWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Sequence ID 11 DIQMTQSPSSVSASVGDRVTITCQASEYISSYLAWYQQKPGKAPKLLIYQASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQTNNAIHTYGGAFGGGTKVE IKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Among these, sequences 10 and 11 are both humanized sequences. To eliminate the ADCC and CDC effects of the antibody, an LALA mutation was introduced into the heavy chain constant region.
[0037] In this specification, “isolated” nucleic acid means nucleic acid molecules separated from components of their natural environment. Isolated nucleic acids include nucleic acid molecules that are normally found in cells containing nucleic acid molecules, but such nucleic acid molecules are located outside of chromosomes or at chromosomal locations different from their natural chromosomal locations.
[0038] In this specification, “isolated nucleic acid encoding an anti-IL-36R monoclonal antibody” means one or more nucleic acid molecules encoding the heavy and light chains of an antibody, including such nucleic acid molecules in a single vector or separate vectors, and such nucleic acid molecules present at one or more locations in a host cell.
[0039] In this specification, “vector” means a nucleic acid molecule capable of amplifying another nucleic acid ligated to it. This term includes vectors that are self-replicating nucleic acid structures, and vectors that have been incorporated into the genome of a host cell into which they have been introduced. Some vectors can guide the expression of the nucleic acid to which they are manipulably ligated. Such vectors are referred to herein as “expression vectors.”
[0040] In this specification, “host cell,” “host cell line,” and “host cell culture” may be used interchangeably and refer to cells into which exogenous nucleic acids have been introduced, including the progeny of such cells. Host cells include “transformers” and “transformed cells,” and include primary transformed cells and their derived progeny (regardless of passage number). Progeny do not have to be exactly the same as the parent cells in terms of nucleic acid contents and may contain mutations. Mutant progeny with the same function or biological activity, screened or selected from the initially transformed cells, are included herein.
[0041] In this specification, “pharmaceutical composition” means a product in which the biological activity of the active ingredient contained herein is activated, and the composition does not contain any additional ingredients that are unacceptably toxic to the subject to whom the formulation is administered.
[0042] In this specification, “pharmaceutically acceptable carrier” means a component of a pharmaceutical composition other than the active ingredient that is non-toxic to the subject. pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0043] In this specification, "monoclonal antibody" generally refers to a human antibody, which can be prepared using techniques well known to those skilled in the art. For example, human antibodies are generally described in van Dijk, MA and van de Winkel, JG, Curr. Opin. Pharmacol. 5:368-374 (2001) and Lonberg, N., Curr. Opin. Immunol. 20:450-459 (2008).
[0044] Antibodies can be prepared by administering immunogens to transgenic animals modified to stimulate the production of fully human antibodies or intact antibodies with human variable regions in response to antigen attack. These animals typically contain some or all of the human immunoglobulin loci, with the endogenous immunoglobulin loci replaced, located extrachromosomally, or randomly incorporated into the animal's body. In such transgenic mice, the endogenous immunoglobulin loci are generally inactivated. For an overview of methods for obtaining human antibodies from transgenic animals, see Lonberg, N., Nat. Biotech. 23:1117-1125 (2005). See also, for example, the XENOMOUSE® technology described in U.S. Patent Nos. 6,075,181 and 6,150,584, the HUMAB® technology described in U.S. Patent No. 5,770,429, the K-MMOUSE® technology described in U.S. Patent No. 7,041,870, and the VELOCIMOUSE® technology described in U.S. Patent Application Publication No. US2007 / 0061900. The human variable regions of such intact antibodies produced from animals can be further modified, for example, by combination with different human constant regions.
[0045] Human antibodies can also be produced by hybridoma-based methods. Human myeloma cells and mouse-human hybrid myeloma cells used for the production of human monoclonal antibodies have been described (see, for example, Kozbor, D., J. Immunol. 133:3001-3005 (1984); Brodeur, B. et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York (1987), pp. 51-63; Boerner, P. et al., Immunol. 147:86-95 (1991)). Human antibodies produced by human B-cell hybridoma technology are also described in Li, J. et al., Proc. Natl. Acad. Sci. USA 103:3557-3562 (2006). Other methods include, for example, those described in U.S. Patent No. 7,189,826 (regarding the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4);265-268 (regarding human-human hybridomas). Human hybridoma technology (trioma technology) is also described in Vollmers, HP and Brandlein, S., Histology and Histopathology 20:927-937 (2005); Vollmers, HP and Brandlein, S., Methods and Findings in Experimental and Clinical Pharmacology 27:185-191 (2005).
[0046] Human antibodies can also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries, and then combining such variable domain sequences with desired human constant domains.
[0047] Human antibodies can also be selected based on autoantibody libraries. That is, human antibodies can be isolated by screening a combination library for one or more antibodies with desired activity. For example, various methods are known in the art for preparing phage display libraries and screening such libraries for antibodies with desired binding properties. This method is outlined, for example, in Hoogenboom, HR et al., Methods in Molecular Biology 178:1-37 (2001), and further, for example, McCafferty, J. et al., Nature 348:552-554 (1990); Clackson, T. et al., Nature 352:624-628 (1991); Marks, J. Det al., J. Mol. Biol. 222:581-597 (1992); Marks, J. Dand Bradbury, A., Methods in Molecular Biology 248:161-175 (2003); Sidhu, S. Set al., J. Mol. Biol. 338:299-310 (2004); Lee, C. et al. This is described in al., J. Mol. Biol. 340:1073-1093 (2004); Fellouse, FA, Proc. Natl. Acad. Sci. USA 101:12467-12472 (2004); and Lee, CV et al., J. Immunol. Methods 284:119-132 (2004).
[0048] As described in Winter, G. et al., Ann. Rev. Immunol. 12:433-455 (1994), some phage display methods involve cloning complete sets of VH and VL genes by polymerase chain reaction (PCR), randomly recombining them in a phage library, and then screening the library for antigen-binding phages. Phages typically present antibody fragments as single-chain Fv(scFv) fragments or Fab fragments. Libraries from immunized sources provide high-affinity antibodies against immunogens without the need to construct hybridomas. Alternatively, as described in Griffiths, A. et al., EMBO J, 12:725-734 (1993), unimmunized repertoires (e.g., from humans) can be cloned to provide a single antibody source against numerous non-self and self-antigens in the absence of immunization. Finally, as described by Hoogenboom, H.R. and Winter, G., J. Mol. Biol. 227:381-388 (1992), unimmunized libraries can also be synthetically generated by cloning unreconstituted V gene segments from stem cells, encoding highly variable CDR3 regions using PCR primers containing random sequences, and reconstituting them in vitro. Patent publications describing human antibody phage libraries include, for example, U.S. Patent No. 5,750,373 and U.S. Patent Publications 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0292936 and 2009 / 0002360.
[0049] The antibody may also be a multispecific antibody, such as a bispecific antibody. A bispecific antibody is a monoclonal antibody that has binding specificity to at least two different sites. Techniques for generating multispecific antibodies include, but are not limited to, the recombinant co-expression of two immunoglobulin heavy-light chain pairs with different specificities (see Milstein, C. and Cuello, AC, Nature 305:537-540 (1983); WO93 / 08829; and Traunecker, A. et al., EMBO J.10:3655-3659 (1991)) and "protuberance-into-cavity" engineering (see, for example, U.S. Patent No. 5,731,168). Furthermore, multispecific antibodies can be produced using manipulated electrostatic steering effects for the generation of antibody Fc heterodimer molecules (International Publication No. 2009 / 089004), crosslinking of two or more antibodies or fragments (see, e.g., U.S. Patent No. 4,676,980 and Brennan, M. et al., Science 229:81-83 (1985)), generation of bispecific antibodies using leucine zippers (see, e.g., Kostelny, SA et al., J. Immunol. 148:1547-1553 (1992)), use of "dual antibody" technology to generate bispecific antibody fragments (see, e.g., Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993)), and use of single-chain Fv (scFv) dimers (see, e.g., Gruber, M. et al.) It can be produced by (see al., J.Immunol. 152:5368-5374 (1994)) and by the preparation of a trispecific antibody (see, for example, Tutt, A. et al., J.Immunol. 147:60-69 (1991)).
[0050] The monoclonal antibodies described herein also include engineered and modified antibodies having three or more functional antigen-binding sites, including "octopus antibodies" (see, for example, U.S. Patent No. 2006 / 0025576).
[0051] The antibodies described herein may also include the multispecific antibodies described in WO2009 / 080251, WO2009 / 080252, WO2009 / 080253, WO2009 / 080254, WO2010 / 112193, WO2010 / 115589, WO2010 / 136172, WO2010 / 145792, and WO2010 / 145793, WO2011 / 117330, WO2012 / 025525, WO2012 / 025530, WO2013 / 026835, WO2013 / 026831, WO2013 / 164325, or WO2013 / 174873.
[0052] The monoclonal antibodies described herein may also be antibody variants if, for example, it is desirable to improve the antibody's binding affinity and / or other biological properties. Amino acid sequence variants of antibodies can be prepared by introducing appropriate modifications to the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions, and / or insertions, and / or substitutions of residues in the amino acid sequence of the antibody. Any combination of deletions, insertions, and substitutions can be used to obtain the final construct, as long as the final construct has the desired properties, such as antigen binding. Therefore, in some embodiments, antibody variants having one or more amino acid substitutions are provided, where the target sites of the substitution mutations include HVR and FR, and for example, amino acid substitutions can be introduced into the target antibody to screen for products with the desired activity, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC. [Examples]
[0053] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods.
[0054] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercially available sources.
[0055] Example 1: Preparation of anti-human IL-36R monoclonal antibody QX009N New Zealand rabbits were immunized with a human interleukin-36 receptor (hIL-36R-Rabbit Fc) that Qyuns had synthesized and expressed. Antigen-binding specific antibody clones were obtained using B cell cloning technology, and monoclonal antibodies bound to human IL-36R and exhibiting human IL-36R inhibitory activity were screened. Cell supernatants were detected, analyzed, and screened using binding ELISA and IL-8 release methods from HT29 cells to select target clones. The above immunization and screening processes were outsourced to a commercial company for completion.
[0056] Ten clones were selected before and after recombinant expression and sequenced. Measurements revealed that the 25# clone had the best cell neutralizing activity. Therefore, the 25# clone was humanized. Homology comparison of human IgG germline sequences (Germlines) was performed using NCBI IgBlast, and IgGHV3-66*01 was selected as the heavy chain CDR transplantation template. The CDR regions of the 25# clone heavy chain (i.e., CDR-H1 (SEQ ID NO: 1), CDR-H2 (SEQ ID NO: 2), and CDR-H3 (SEQ ID NO: 3)) were transplanted into the framework region of IgGHV3-66*01. IGKV1-12*01 was selected as the light chain CDR transplantation template, and the CDR regions of the 25# clone light chain (i.e., CDR-L1 (SEQ ID NO: 4), CDR-L2 (SEQ ID NO: 5), and CDR-L3 (SEQ ID NO: 6)) were transplanted into the framework region of IGKV1-12*01. By performing a reverse mutation on a specific site in the framework region and a site-directed mutation on the CDR region, we obtained the variable region of the monoclonal antibody QX009N described in this application. Finally, the sequence of the humanized heavy chain variable region is shown in SEQ ID NO: 7, and the amino acid sequence of the humanized light chain variable region is shown in SEQ ID NO: 8.
[0057] The heavy chain gene (SEQ ID NO: 10) and the light chain variable region gene (SEQ ID NO: 8) were obtained by PCR amplification. The heavy chain expression plasmid pQX1 was double-digested using HindIII and BamHI, and the light chain expression plasmid pQX2.3 was double-digested using HindIII and BsiWI. The PCR-amplified genes were then inserted into the corresponding expression plasmids using infusion recombinase to construct the heavy chain expression plasmid pQX2.1-25VH-Hu12 and the light chain expression plasmid pQX2.3-25VK-Hu17.
[0058] Figure 1 shows the results of detecting PCR-amplified heavy chain gene fragments, light chain variable region gene fragments, and double-digested plasmids by nucleic acid electrophoresis. As can be seen from the results in Figure 1, the PCR amplification results of the heavy chain and light chain variable region of the antibody, as well as the double-digestion results of the heavy chain expression plasmid and light chain expression plasmid, show that the sizes of the heavy chain and light chain plasmids are approximately 5000 bp, the heavy chain is approximately 1469 bp, and the light chain variable region is approximately 441 bp.
[0059] ExpiCHO-S cells were simultaneously transfected with the correctly sequenced heavy chain expression plasmid pQX2.1-25VH-Hu12 (the amino acid sequence of the heavy chain expressed by it is shown in SEQ ID NO: 10) and the light chain expression plasmid pQX2.3-25VK-Hu17 (the amino acid sequence of the light chain expressed by it is shown in SEQ ID NO: 11). The day before transfection, 3 × 10⁶ ExpiCHO-S cells were passed through for pre-transfection passage. 6 The solution was diluted to cells / ml. On the day of transfection, the cell density was increased to 6 × 10⁻⁶. 6 The cells were diluted to cells / ml and 25 ml of cells were placed in a 125 ml shaking flask for transfection. The transfection and expression process is shown in Figure 2.
[0060] Six days after transfection, the culture supernatant was collected and purified in one step using Protein A. The purified antibody was detected by SDS-PAGE electrophoresis and named QX009N(HZD25-54). Figure 3 shows the results of protein electrophoresis detection of this antibody. Protein electrophoresis was performed on a denaturing reduced gel, and as can be seen from the results shown in Figure 3, there are two bands, with sizes of approximately 50 kDa and 25 kDa, respectively, which are consistent with the theoretical molecular weights of the heavy chain (49.0 kDa) and light chain (23.4 kDa).
[0061] Example 2 Equilibrium dissociation constant (K D ) measurement The affinity of QX009N (HZD25-54) to human IL-36R was detected using a Biacore T200, and all processes were performed at 25°C. Using a commercially available Protei A protein chip, an appropriate amount of antibody was immobilized by capture so that the Rmax was approximately 50 RU and the capture flow rate was 10 μl / min. The antigen was serially diluted, the instrument flow rate was switched to 30 μl / min, and the reference channel and antibody immobilization channel were run in order from lowest to highest concentration, with buffer run as a negative control. After each binding and dissociation was complete, the chip was regenerated with pH 1.5 glycine. Using the instrument's software, the 1:1 binding model in the Kinetics option was selected and fitted, and the antibody binding rate constant k was determined. a , dissociation rate constant k d , and the equilibrium dissociation constant K D The value was calculated.
[0062] Furthermore, the affinity of QX009N(HZD25-54) was compared with the affinity of spesolimab, a monoclonal antibody against human IL-36R currently in Phase 3 clinical trials. The detection method for known antibodies was the same as the detection method for QX009N. The results are shown in Table 1. Here, spesolimab was produced by the inventors by constructing an expression plasmid based on the B6 sequence provided in patent US9023995B2 and transiently transfecting ExpiCHO-S cells with it. [Table 1] The data in the table shows the average value calculated from testing each sample three times.
[0063] Example 3: Activity of QX009N (HZD25-54) and spesolimab analogs to neutralize human IL-36 (α, β, γ)-induced STAT3 phosphorylation in HT29 reporter gene cells. Using an HT29 reporter gene cell line, the activity of QX009N (HZD25-54), which antagonizes the phosphorylation of the human IL-36 (α, β, γ)-mediated intracellular signaling molecule STAT3 via IL-36R-IL-1RAcp, was measured as follows: 40,000 cells were added to each well of a 96-well cell culture plate in 100 μl volumes and cultured overnight at 37°C and 5% CO2. Antibodies were added to the cells and incubated for 1 hour, with final antibody concentrations ranging from 0 to 10,000 ng / ml. After incubation, 50 μl / well of recombinant human IL-36 mixture (containing recombinant human IL-36α 2 ng / ml, recombinant human IL-36β 1 ng / ml, and recombinant human IL-36γ 40 ng / ml) was added and cultured for 24 hours at 37°C and 5% CO2. The cell culture supernatant was discarded, and 120 μl of ONE Glo Luciferase Reagent was added to each well and allowed to react for 10 minutes. 80 μl was taken from each well and transferred to a white 96-well plate. Luminescence fluorescence signal values were detected, and the antagonistic activity of the antibody was analyzed by plotting dose-response curves. The dose-response curves are shown in Figure 4.
[0064] As can be seen from the results shown in Figure 4, QX009N(HZD25-54) can inhibit the phosphorylation of STAT3 in HT29 reporter gene cells induced by human IL-36(α,β,γ), and the IC of QX009N(HZD25-54) inhibiting the phosphorylation of STAT3 in HT29 reporter gene cells induced by human IL-36(α,β,γ) 50is 2.16ng / ml, which is the IC of the spesolimab analog that inhibits STAT3 phosphorylation in HT29 reporter gene cells induced by human IL-36 (α, β, γ) 50 is 15.67ng / ml.
[0065] Example 4 Activities of QX009N (HZD25-54) and spesolimab analog that neutralize the release of CXCL-1 and IL-8 from HT29 cells induced by human IL-36 (α, β, γ) Using the HT29 cell line, the activity of QX009N (HZD25-54) that antagonizes human IL-36 (α, β, γ), which induces the release of CXCL-1 and IL-8 from HT29 cells via IL-36R-IL-1RAcp, was measured as follows. 40,000 cells were added to each well of a 96-well cell culture plate in a volume of 100μl, and cultured overnight at 37°C with 5% CO₂. The antibody was added to the cells and incubated for 1 hour, with the final concentration of the antibody ranging from 0 to 10,000ng / ml. After incubation, 50μl / well of a recombinant human IL-36 mixture (containing 1ng / ml recombinant human IL-36α, 0.2ng / ml recombinant human IL-36β, and 4ng / ml recombinant human IL-36γ) was added, followed by culturing at 37°C with 5% CO₂ for 24 hours. Cell culture supernatant was collected, the expression of CXCL-1 and IL-8 in the supernatant was detected using a sandwich ELISA method, and a dose-response curve was plotted to analyze the antagonistic activity of the antibody. The dose-response curve is shown in Figure 5.
[0066] As can be seen from the results shown in Figure 5, QX009N (HZD25-54) can inhibit the release of CXCL-1 and IL-8 from HT29 cells induced by human IL-36 (α, β, γ), and the IC of QX009N (HZD25-54) that inhibits the release of CXCL-1 and IL-8 from HT29 cells induced by human IL-36 (α, β, γ) 50 are 2.21ng / ml and 1.53ng / ml respectively, and the IC of the spesolimab analog that inhibits the release of CXCL-1 and IL-8 from HT29 cells induced by human IL-36 (α, β, γ) 50These values are 12.29 ng / ml and 11.47 ng / ml, respectively.
[0067] Example 5: Activity of QX009N (HZD25-54) and spesolimab analogs to neutralize the release of CXCL-1 and IL-8 from A431 cells induced by human IL-36 (α, β, γ). Using the A431 cell line, the activity of QX009N (HZD25-54), which antagonizes human IL-36 (α, β, γ) that induces the release of CXCL-1 and IL-8 from A431 cells via IL-36R-IL-1RAcp, was measured as follows: 40,000 cells were added to each well of a 96-well cell culture plate in 100 μl volumes and cultured overnight at 37°C and 5% CO2. Antibodies were added to the cells and incubated for 1 hour, with final antibody concentrations ranging from 0 to 10,000 ng / ml. After incubation, 50 μl / well of recombinant human IL-36 mixture (containing recombinant human IL-36α 20 ng / ml, recombinant human IL-36β 2 ng / ml, and recombinant human IL-36γ 50 ng / ml) was added and cultured for 24 hours at 37°C and 5% CO2. Cell culture supernatants were collected, and the expression of CXCL-1 and IL-8 in the supernatant was detected using the sandwich ELISA method. The antagonistic activity of the antibodies was analyzed by plotting dose-response curves. The dose-response curves are shown in Figure 6.
[0068] As can be seen from the results shown in Figure 6, QX009N(HZD25-54) can inhibit the release of CXCL-1 and IL-8 from A431 cells induced by human IL-36(α,β,γ), and the IC of QX009N(HZD25-54) inhibits the release of CXCL-1 and IL-8 from A431 cells induced by human IL-36(α,β,γ). 50 The ICs were 4.12 ng / ml and 2.89 ng / ml, respectively, and are for the ICs of spesolimab analogs that inhibit the release of CXCL-1 and IL-8 from A431 cells induced by human IL-36 (α, β, γ). 50 These values are 22.46 ng / ml and 16.02 ng / ml, respectively.
[0069] Example 6: Activity of QX009N (HZD25-54) and spesolimab analogs to neutralize IL-8 release from human PBMC cells induced by human IL-36β. The activity of QX009N (HZD25-54), which antagonizes human IL-36β that induces IL-8 release from human PBMC cells via IL-36R-IL-1RAcp, was measured using human PBMC cells as follows. PBMCs were isolated from human venous blood (collected from healthy adult volunteers) by density gradient centrifugation. 20,000 cells were added to each well of a 96-well cell culture plate in 100 μl volumes. The antibody was added to the PBMCs and incubated for 1 hour, with the final antibody concentration ranging from 0 to 5,000 ng / ml. After incubation, 50 μl / well of recombinant human IL-36β at 10 ng / ml was added, and the cells were cultured at 37°C and 5% CO2 for 24 hours. The cell culture supernatant was collected, and IL-8 expression in the supernatant was detected using sandwich ELISA. The antagonistic activity of the antibody was analyzed by plotting a dose-response curve. The dose-response curve is shown in Figure 7.
[0070] As can be seen from the results shown in Figure 7, QX009N(HZD25-54) can inhibit the release of IL-8 from human PBMC cells induced by human IL-36β, and the IC of QX009N(HZD25-54) activity inhibiting the release of IL-8 from human PBMC cells induced by human IL-36β is 50 The IC of activity of a spesolimab analog that inhibits the release of IL-8 from human PBMC cells induced by human IL-36β was 4.69 ng / ml. 50 The value is 26.59 ng / ml.
Claims
1. An anti-human interleukin 36 receptor (IL-36R) monoclonal antibody comprising three heavy chain complementarity-determining regions CDR-H1, CDR-H2, and CDR-H3, and three light chain complementarity-determining regions CDR-L1, CDR-L2, and CDR-L3, The amino acid sequence of CDR-H1 is shown in Sequence ID No. 1; The amino acid sequence of CDR-H2 is shown in Sequence ID No. 2; The amino acid sequence of CDR-H3 is shown in Sequence ID No. 3; The amino acid sequence of CDR-L1 is shown in Sequence ID No. 4; The amino acid sequence of CDR-L2 is shown in Sequence ID No. 5; The amino acid sequence of CDR-L3 is shown in SEQ ID NO: 6, which is the monoclonal antibody.
2. It includes heavy chain variable regions and light chain variable regions. The amino acid sequence of the heavy chain variable region is shown in Sequence ID No.
7. The monoclonal antibody according to claim 1, wherein the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
8.
3. An isolated nucleic acid encoding the monoclonal antibody according to claim 1 or 2.
4. A host cell comprising the nucleic acid described in claim 3.
5. A method for producing a monoclonal antibody, comprising culturing the host cells described in claim 4 to produce the monoclonal antibody described in claim 1 or 2.
6. A pharmaceutical composition comprising a monoclonal antibody according to claim 1 or 2 and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition according to claim 6, used for the treatment of diseases related to IL-36R-mediated signaling.
8. The pharmaceutical composition according to claim 7, wherein the disease associated with the IL-36R-mediated signaling is selected from dermatitis, psoriasis, inflammatory bowel disease, arthritis, systemic lupus erythematosus, inflammatory lung disease, and chronic kidney disease.
9. The pharmaceutical composition according to claim 8, wherein the disease associated with the IL-36R-mediated signaling is selected from generalized pustular psoriasis, palmoplantar pustulosis, atopic dermatitis, inflammatory bowel disease, chronic obstructive pulmonary disease, psoriasis vulgaris, psoriatic arthritis, rheumatoid arthritis, or asthma.
10. Use of a monoclonal antibody according to claim 1 or 2 in the preparation of a drug for treating a disease related to IL-36R signaling.
11. The diseases associated with the aforementioned IL-36R-mediated signaling are selected from dermatitis, psoriasis, inflammatory bowel disease, arthritis, systemic lupus erythematosus, inflammatory lung disease, and chronic kidney disease. The use described in claim 10.
12. The use according to claim 11, wherein the disease associated with the IL-36R-mediated signaling is selected from generalized pustular psoriasis, palmoplantar pustulosis, atopic dermatitis, inflammatory bowel disease, chronic obstructive pulmonary disease, psoriasis vulgaris, psoriatic arthritis, rheumatoid arthritis, or asthma.
Citation Information
Patent Citations
Antibody targeting interleukin 36R, and preparation method and application of antibody
CN112094349A
Anti-IL-36R antibody
JP2015500633A
Antibodies against interleukin 36 receptor (il-36r)
JP2018512157A
Anti-IL36R antibody
JP2021530229A
Anti-human il-36r antibody and application thereof
WO2022166977A1
